Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of gastroparesis
3.2.1.2 Growing patient preference for non-invasive treatment
3.2.1.3 Rising awareness and diagnosis rate
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of limited treatment options
3.2.2.2 Regulatory challenges
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Company positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Prokinetic agents
5.3 Antiemetic drugs
5.4 Proton pump inhibitors
5.5 Other drug classes
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Diabetes gastroparesis
6.3 Idiopathic gastroparesis
6.4 Post-surgical gastroparesis
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 OTC drugs
8.3 Prescription drugs
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021– 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 AbbVie Inc,
11.3 AstraZeneca PLC
11.4 Bayer AG
11.5 Cipla Ltd.
11.6 Evoke Pharma
11.7 Pfizer Inc.
11.8 Salix Pharmaceuticals
11.9 Takeda Pharmaceutical Inc.
11.10 Teva Pharmaceutical Inc.
